We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 461

Application for an order of prohibition is dismissed for a unit dose patent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 23 2015

The Court found that Mylan’s allegations of lack of utility, anticipation and obviousness were justified. As a result, the application was dismissed

Application for an order of prohibition is dismissed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 23 2015

The Court found that Teva’s allegation of obviousness was justified. As a result, the application was dismissed

Canada patented medicines: Federal Court of Appeal confirms mootness of innovator appeals after generic marketing authorization is granted

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • February 17 2015

"Asking a court to prohibit a notice of compliance after it has issued is like asking someone to close the barn door after the horses have escaped."

Federal Court of Appeal holds PMNOC appeal moot - innovator argument on CETA equal access to appeal right rejected

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • February 12 2015

Janssen Inc. et al. (Janssen) appealed from the decision of Justice Barnes of the Federal Court refusing to prohibit the Minister of Health from

Finding of non-infringement upheld on appeal

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 9 2015

The Court of Appeal dismissed an appeal of a decision of the Court in a NOC proceeding finding that an allegation of non-infringement was justified

Appeal in NOC Proceeding dismissed as moot

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 9 2015

The Court of Appeal granted Teva’s motion to have an appeal from a NOC Proceeding dismissed as moot. The Respondent’s request for an oral hearing of

Federal Court rejects generic’s non-infringing alternative defence and awards compound interest for patent infringement damages

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • February 2 2015

On January 23, 2015, the Federal Court released its public reasons for Judgment granting Eli Lilly and Company and Eli Lilly Canada, Inc

Canadian patent judge takes a hard stand against generic CIALIS (tadalafil)

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • January 26 2015

On January 7, 2015, Justice de Montigny of the Federal Court released his judgment and reasons in Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC

Order of prohibition granted in respect of use patent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 26 2015

The Court found that Mylan’s allegations of lack of utility, and specifically lack of sound prediction, and obviousness-type double patenting were

Federal Court revisits the issue of medical uses

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • January 22 2015

In AbbVie Biotechnology Ltd v Canada (Attorney General), 2014 FC 1251, rendered December 22, 2014, the Federal Court allowed AbbVie's appeal from a